Tagged with Association,

Romania Valentina Băicuianu and Adrian Grecu of the APMGR, share their insights on the deteriorating environment for generics in Romania, with unfavourable pricing methodology and a rising and an unpredictable clawback tax. They reveal the solutions that the generics industry has proposed to authorities and outline their continued endeavours to convince…

UAE The Pharmaceutical Research and Manufacturers Association Gulf (PHRMAG) represents the region’s leading innovative biopharmaceutical research companies. Dream Samir, secretary general of the organization, discusses PHRMAG’s efforts to continue impacting the region’s pharmaceutical industry, the priorities of the private sector and why the UAE is well positioned to compete on the…

Belgium Joris Van Assche, managing director of the Belgian association for accessible medicines, Medaxes, highlights the need for a stronger policy to create a more positive environment for generic and biosimilar medicines. He also outlines the important role the off-patent sector plays in the long-term sustainability of Belgium’s universal healthcare system.…

Romania The Romanian Association of the Self-Care Industry (RASCI) was established in 2016 as the “voice” of the Romanian consumer healthcare industry. Diana Mereu, CEO of RASCI, discusses the association’s mission, the impact of Romania’s political volatility on the industry, the future impact of digitalization on the self-care market, and the…

Czech Republic Darina Hrdličková, chairwoman of the Association of Contract Research Organizations in the Czech Republic (ACRO-CZ), gives an overview of her new priorities and mission since taking over the position in 2018, and how dedicated she is to showcase the strengths of the Czech healthcare system and the advantages of the…

Czech Republic Bernard Bauer, CEO and board member at the German-Czech Chamber of Industry and Commerce, discusses the factors that make the German-Czech collaboration such a natural and powerful one, out of which the two countries’ common industrial tradition plays a key role. Furthermore, Bauer assesses the evolution of bilateral trade relations,…

USA The AAM’s Chip Davis gives an account of his agenda for 2020, how the association is driving policy in a complex healthcare environment of multiple public and private actors and offers insight as to why there is great room for improvement in the uptake of biosimilar drugs.   The question,…

Europe The EFPIA’s Nathalie Moll outlines the case for a new EU-wide industrial strategy with biopharmaceuticals at its heart.   The pharmaceutical industry is an area of strategic economic and social value where the EU is a global player   Europe has a history as a world leader in medical innovation,…

UAE Cara Nazari of AmCham Dubai discusses her role in helping shape the chamber into a more business-minded institution, why Dubai is an attractive destination for investment, improving healthcare stakeholder relations, and fostering ‘Open Innovation’.   Healthcare is a top priority for the UAE. Ensuring quality care for its population is…

Hungary Dr Péter Holchacker, director of the Hungarian Association of Innovative Pharmaceutical Manufacturers (AIPM), shares his insights on the key activities of the organisation, the collaborations it fosters with authorities and multinational pharmaceutical companies, the attractiveness of the Hungarian market, and the AIPM’s role in improving the country’s regulatory and reimbursement…

UAE Samir Khalil, executive director for the Pharmaceutical Research and Manufacturers of America (PhRMA) Middle East and Africa (MEA), reveals why the US industry is investing in MEA, the challenges presented by the lack of intellectual property enforcement in the region, and the shifting of focus from manufacturing to broader research…

Czech Republic Jakub Dvořáček, CEO of the Czech Association of Innovative Pharmaceutical Industry (AIFP), describes the thorough review of the reimbursement scheme the association has worked on alongside other key stakeholders in Czech healthcare and evaluates the major change this will bring in terms of access to innovative medicines for patients. Furthermore,…